
RadNet Shares Drop Amid AI Strategy Concerns and Short Selling
RadNet's touted AI division contributes less than 5% of revenue and appears to be overhyped, with its stock valuation driven by speculative rebranding rather than solid growth or external customer traction. The company's financial disclosures are inconsistent, and much of its reported growth is attributed to internal sales and center consolidations that inflate same-center sales figures. Insiders have sold significant shares, raising concerns about the true value of RadNet's AI ambitions amid a challenging healthcare reimbursement environment and fierce market competition.








